# PEAQX NMDA antagonist research details clarified

**Published:** 2026-08-13T00:56:10.458Z  
**Topic:** peaq  
**Sentiment:** neutral  
**Publisher:** TrendWatcher — https://www.trendwatcher.in/article/116c4672-7cdc-4e3a-9934-d625d59fbdda

PEAQX shows 5‑fold receptor affinity difference and 270 nM IC50 for NMDA 1A/2A, key for neuroscience studies.

PEAQX, a competitive NMDA receptor antagonist, exhibits a 5‑fold affinity gap between GluN1/GluN2A and GluN1/GluN2B receptors, a detail that refines earlier claims of 100‑fold selectivity [1].

| At a glance | |
|---|---|
| Receptor affinity gap | 5‑fold (GluN1/GluN2A vs. GluN1/GluN2B) |
| IC₅₀ (hNMDA 1A/2A) | 270 nM |
| IC₅₀ (hNMDA 1A/2B) | 29.6 µM |
| Primary use | Research‑grade NMDA antagonist |

## Revised pharmacology profile  
Early reports described PEAQX as 100‑fold selective for GluN1/GluN2A receptors, but more detailed Ki measurements show the selectivity is only five‑fold [1]. This adjustment aligns with data from the NCATS substance database, which lists an IC₅₀ of 270 nM for the 1A/2A subtype and 29.6 µM for the 1A/2B subtype [2]. The compound is also noted for its potent anticonvulsant activity in animal models [1].

## Research applications and dosing  
PEAQX is supplied for laboratory use only, with typical in‑vitro concentrations ranging from 3 µM to 5 µM to induce apoptosis or inhibit calcium influx in neuronal cultures [3][4]. In vivo studies report sub‑cutaneous doses of 10–40 mg/kg producing dose‑dependent increases in caspase‑3 activity and improvements in motor function in rats [4]. These findings support its role in probing NMDA‑mediated pathways and evaluating neuroprotective strategies.

**Key metrics**  

| Metric | Value |
|---|---|
| Molecular weight | 454.21 g mol⁻¹ |
| CAS number | 459836‑30‑7 |
| Purity (batch) | >98 % |

## What to watch  
- Upcoming peer‑reviewed publications that may further refine the selectivity ratio or report new in‑vivo efficacy data.  
- Regulatory filings, if any, that could shift the compound from research‑only status toward clinical investigation.  
- Supply chain updates from vendors such as GLP Bio or MedChemExpress, which could affect availability for labs.

The clarified selectivity and potency metrics of PEAQX sharpen its utility as a tool compound for dissecting NMDA receptor subunit functions, but the gap between pre‑clinical promise and therapeutic application remains to be bridged.

## Sources
1. Wikipedia — [PEAQX](https://en.wikipedia.org/wiki/PEAQX)
2. Drugs — [PEAQX](https://drugs.ncats.io/substance/LE8K7M4APN)
3. Glpbio — [PEAQX | CAS NO.:459836-30-7 | GlpBio](https://www.glpbio.com/peaqx.html)
4. File — [PEAQX | MedChemExpress](https://file.medchemexpress.com/batch_PDF/HY-12294/PEAQX-DataSheet-MedChemExpress.pdf)
5. Invivochem — [PEAQX | NMDAR | CAS 459836-30-7 | Buy PEAQX from Supplier...](https://www.invivochem.com/peaqx.html)

---
Cite as: TrendWatcher, "PEAQX NMDA antagonist research details clarified", https://www.trendwatcher.in/article/116c4672-7cdc-4e3a-9934-d625d59fbdda